Publications by authors named "A Mehran Mostafavifar"
Background: The American Society of Hematology Guidelines for the management of venous thromboembolism recommend against the use of anti-Xa monitoring for assessing enoxaparin dosing based on a low level of evidence associating supratherapeutic levels with an increased risk of bleeding. However, institutions still utilize anti-Xa levels in select patient populations with altered volume of distribution and/or excretion to monitor and adjust therapy.
Objective: The primary objective of this study was to identify risk factors associated with supratherapeutic peak anti-Xa levels (≥1.